Online inquiry

IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13870MR)

This product GTTS-WQ13870MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&MS4A1 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000733.4; NM_021950.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 931
UniProt ID P07766; P11836
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13870MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10028MR IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA L19-131 I
GTTS-WQ3013MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Anti-Beta7
GTTS-WQ5005MR IVTScrip™ mRNA-Anti-GP, c4G7-N(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA c4G7-N
GTTS-WQ3990MR IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BG9924
GTTS-WQ11247MR IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MEDI4736
GTTS-WQ14467MR IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RO-7105705
GTTS-WQ6233MR IVTScrip™ mRNA-Anti-RABVgp4, CR57(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CR57
GTTS-WQ1535MR IVTScrip™ mRNA-Anti-MSTN, ACE-031(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ACE-031
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW